Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026. Solid has entered into non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid. The Company expects to file an IND for its first cardiac gene therapy candidate.